Showing results (391-400 of 437) with videos related to

Sort By:
Pageof 44
Medcomm|February 20, 2026
Spironolactone and Fibrosis in Heart Failure Risk: Machine Learning Analysis of HOMAGE Trial Plasma ProteomicsSusana Ravassa, Nicolas Girerd, Frank Edelman, et al.
ESC Heart Failure|November 8, 2023
Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trialDiogo Santos-Ferreira, Sílvia O Diaz, João Pedro Ferreira, et al.
European Journal of Heart Failure|January 18, 2020
Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trialPierpaolo Pellicori, João Pedro Ferreira, Beatrice Mariottoni, et al.
Journal of Cardiac Failure|December 21, 2021
The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE TrialJob A J Verdonschot, JoÃo Pedro Ferreira, Anne Pizard, et al.
JAMA|February 1, 2022
Effect of Moderate Hypothermia vs Normothermia on 30-Day Mortality in Patients With Cardiogenic Shock Receiving Venoarterial Extracorporeal Membrane Oxygenation: A Randomized Clinical TrialBruno Levy, Nicolas Girerd, Julien Amour, et al.
European Journal of Heart Failure|October 28, 2024
Proteomic biomarkers and pathway analysis for progression to heart failure in three epidemiological representative cohortsAnna Dieden, Nicolas Girerd, Filip Ottosson, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|September 6, 2024
Effects of spironolactone on exercise blood pressure in patients at increased risk of developing heart failure: report from the HOMAGE trialFang-Fei Wei, Pierpaolo Pellicori, João Pedro Ferreira, et al.
ESC Heart Failure|August 11, 2024
Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failureFang-Fei Wei, Beatrice Mariottoni, De-Wei An, et al.
European Journal of Heart Failure|November 29, 2021
Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trialSusana Ravassa, Begoña López, João Pedro Ferreira, et al.
European Journal of Heart Failure|June 15, 2022
The association between markers of type I collagen synthesis and echocardiographic response to spironolactone in patients at risk of heart failure: findings from the HOMAGE trialMasatake Kobayashi, Nicolas Girerd, João Pedro Ferreira, et al.
Pageof 44